Sanctuary Advisors LLC Acquires New Position in Bristol Myers Squibb Company $BMY

Sanctuary Advisors LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 384,190 shares of the biopharmaceutical company’s stock, valued at approximately $22,137,000.

A number of other large investors have also modified their holdings of the business. Davis Asset Management L.P. purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. boosted its holdings in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Finally, Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BMY shares. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Truist Financial restated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Bank of America cut their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.06 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The business has a fifty day moving average of $60.55 and a 200-day moving average of $59.39. The stock has a market cap of $136.98 billion, a price-to-earnings ratio of 14.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.